Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Aeris Capital

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 38
Average round size
The average size of a deal this fund participated in
Portfolio companies 20
Rounds per year 2.53
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 12
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Therapeutics
  • Mobile

The company was established in Europe in Switzerland. The leading representative office of defined VC is situated in the Pfaffikon.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Aeris Capital, startups are often financed by Mohr Davidow Ventures, Kleiner Perkins, Aberdare Ventures. The meaningful sponsors for the fund in investment in the same round are Mohr Davidow Ventures, BioMedPartners, Life Sciences Partners. In the next rounds fund is usually obtained by Venrock, EDBI, Aster.

We also calculated 4 valuable employees in our database.

The average startup value when the investment from Aeris Capital is 50-100 millions dollars. The important activity for fund was in 2014. The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. This Aeris Capital works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2014. The fund is constantly included in 2-6 deals per year.

Among the most popular portfolio startups of the fund, we may highlight Butterfly Network, Mode Media, GenomeDx Biosciences. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Biotechnology, Health Diagnostics.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Aeris Capital:
Typical Co-investors
Aeris Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Aeris Capital:

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alteon Websystems California, San Jose, United States
Czar Capital England, London, United Kingdom
GrowthWorks Atlantic Venture Fund Canada, Halifax, Nova Scotia
GSTC Health Innovations -
Guangzhou Dangui Touzi Youxian Gongsi China, Guangdong, Guangzhou
Hambrecht & Quist California, San Francisco, United States
JAPAN Creative Platform Group Japan, Tokyo
Krantz Holdings Beverly Hills, California, United States
Lantern Capital Central, Central Region, Singapore
mktg New York, New York, United States
Operating Venture Capital Louisiana, New Orleans, United States
Point West Ventures Alpine, United States, Utah
PULLUP Japan, Tokyo
Renhuai Jiu Tou China, Guizhou, Zunyi
Splice Capital Andhra Pradesh, Hyderabad, India
Stream Hill Angels Beijing, Beijing, China
Sungy Mobile China, Guangdong, Guangzhou
Tango Netherlands, Utrecht, Utrecht
Yucaipa Corporate Initiatives Fund California, Los Angeles, United States
Yunxuetang China, Jiangsu, Suzhou

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

GenomeDx Biosciences

Health Care
$6M27 Jun 2017 Vancouver, British Columbia, Canada


Health Care
$17M07 Jun 2016 Mountain View, California, United States

Solstice Biologics

$4M30 Dec 2015 San Francisco, California, United States


Health Care
$22M01 Oct 2015 Heidelberg, Baden-Württemberg, Germany


Health Care
$23M21 May 2015 Mountain View, California, United States


Health Diagnostics
$17M20 Nov 2014 Germany, Baden-Württemberg, Germany

Butterfly Network

Health Care
Medical Device
Personal Health
$100M02 Nov 2014 Connecticut, United States


Health Care
$18M23 Sep 2014 Mountain View, California, United States


Health Care
$15M02 Sep 2014 Heidelberg, Baden-Württemberg, Germany


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Aeris Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: